- Approval is based on KEYNOTE-189, Ph III study where Keytruda combined with ALIMTA and Pt. CT showed improved results vs CT
- KEYNOTE-189 (Keytruda +pemetrexed and Pt. CT vs CT alone): mPFS (8.8 vs 4.9mos); ORR (48% vs 19%); mDOR (11.2 vs 7.8mos); reducing death risk by half
- Keytruda was first approved in 2017 in combination with pemetrexed and carboplatin by FDA for 1L nonsq. mNSCLC from Ph II (KEYNOTE-021)
Click here to read full press release/ article | Ref: Merck & Co. | Image: Merck & Co.